Drug Discovery and Development

1. Drug Discovery and Development How are drugs discovered and developed?

2. Choose a disease • Choose a drug target • Identify a “bioassay” bioassay = A test used to determine biological activity.

3. Find a “lead compound” “lead compound” = structure that has some activity against the chosen target, but not yet good enough to be the drug itself. • If not known, determine the structure of the “lead compound”

4. Synthesize analogs of the lead • Identify Structure-Activity-Relationships (SAR’s) • Synthesize analogs of the lead • Identify Structure-Activity-Relationships (SAR’s)

5. Identify the “pharmacophore” pharmacophore = the structural features directly responsible for activity • Optimize structure to improve interactions with target

6. Determine toxicity and efficacy in animal models.

7. Determine pharmacodynamics and pharmacokinetics of the drug. • Pharmacodynamics explores what a drug does to the body, whereas pharmacokinetics explores what the body does to the drug.

8. Patent the drug • Continue to study drug metabolism • Continue to test for toxicity

9. Design a manufacturing process • Carry out clinical trials • Market the drug

10. Choosing a Disease • Pharmaceutical companies are commercial enterprises • Pharmaceutical companies will, therefore, tend to avoid products with a small market (i.e. a disease which only affects a small subset of the population)

11. Choosing a Disease • Pharmaceutical companies will also avoid products that would be consumed by individuals of lower economic status (i.e. a disease which only affects third world countries)

12. Choosing a Disease (cont.) • Most research is carried out on diseases which afflict “first world” countries: (e.g. cancer, cardiovascular diseases, depression, diabetes, flu, migraine, obesity).

13. The Orphan Drug Act • The Orphan Drug Act of 1983 was passed to encourage pharmaceutical companies to develop drugs to treat diseases which affect fewer than 200,000 people in the US

14. Under this law, companies who develop such a drug are entitled to market it without competition for seven years. • This is considered a significant benefit, since the standards for patent protection are much more stringent.

15. Identifying a Drug Target • Drug Target = specific macromolecule, or biological system, which the drug will interact with • Sometimes this can happen through incidental observation…

16. Identifying a Drug Target (cont.) • Example: In addition to their being able to inhibit the uptake of noradrenaline, the older tricyclic antidepressants were observed to “incidentally” inhibit serotonin uptake. Thus, it was decided to prepare molecules which could specifically inhibit serotonin uptake. It wasn’t clear that this would work, but it eventually resulted in the production of fluoxetine (Prozac).

17. The mapping of the human genome should help! • In the past, many medicines (and lead compounds) were isolated from plant sources. • Since plants did not evolve with human beings in mind, the fact that they posses chemicals which results in effects on humans is incidental.

18. Having the genetic code for the production of an enzyme or a receptor may enable us to over-express that protein and determine its structure and biological function. If it is deemed important to the disease process, inhibitors (of enzymes), or antagonists or agonists of the receptors can be prepared through a process called rational drug design.

19. Simultaneously, Chemistry is Improving! • This is necessary, since, ultimately, plants and natural sources are not likely to provide the cures to all diseases. • In a process called “combinatorial chemistry” large numbers of compounds can be prepared at one time. • The efficiency of synthetic chemical transformations is improving.

20. Selectivity is Important! • e.g. targeting a bacterial enzyme, which is not present in mammals, or which has significant structural differences from the corresponding enzyme in mammals

21. The Standards are Being Raised • More is known about the biological chemistry of living systems • For example: Targeting one subtype of receptor may enable the pharmaceutical chemist to avoid potentially troublesome side effects.

22. Problems can arise • Example: The chosen target, may over time, lose its sensitivity to the drug • Example: The penicillin-binding-protein (PBP) known to the the primary target of penicillin in the bacterial species Staphylococcus aureus has evolved a mutant form that no longer recognizes penicillin.

23. Choosing the Bioassay • Definitions: • In vitro: In an artificial environment, as in a test tube or culture media • In vivo: In the living body, referring to tests conductedin living animals • Ex vivo: Usually refers to doing the test on a tissue taken from a living organism.

24. Choosing the Bioassay (cont.) In vitro testing • Has advantages in terms of speed and requires relatively small amounts of compound • Speed may be increased to the point where it is possible to analyze several hundred compounds in a single day (high throughput screening) • Results may not translate to living animals

25. Choosing the Bioassay (cont.) In vivo tests • More expensive • May cause suffering to animals • Results may be clouded by interference with other biological systems

26. Finding the Lead Screening Natural Products • Plants, microbes, the marine world, and animals, all provide a rich source of structurally complex natural products.

27. It is necessary to have a quick assay for the desired biological activity and to be able to separate the bioactive compound from the other inactive substances • Lastly, a structural determination will need to be made

28. Finding the Lead (cont.) Screening synthetic banks • Pharmaceutical companies have prepared thousands of compounds • These are stored (in the freezer!), cataloged and screened on new targets as these new targets are identified

29. Finding the Lead (cont.) Using Someone Else’s Lead • Design structure which is similar to existing lead, but different enough to avoid patent restrictions. • Sometimes this can lead to dramatic improvements in biological activity and pharmacokinetic profile. (e.g. modern penicillins are much better drugs than original discovery).

30. Finding the Lead (cont.) Enhance a side effect

31. Use structural similarity to a natural ligand

32. Computer-Assisted Drug Design • If one knows the precise molecular structure of the target (enzyme or receptor), then one can use a computer to design a perfectly-fitting ligand. • Drawbacks: Most commercially available programs do not allow conformational movement in the target (as the ligand is being designed and/or docked into the active site). Thus, most programs are somewhat inaccurate representations of reality.

33. Serendipity: a chance occurrence • Must be accompanied by an experimentalist who understands the “big picture” (and is not solely focused on his/her immediate research goal), who has an open mind toward unexpected results, and who has the ability to use deductive logic in the explanation of such results. • Example: Penicillin discovery • Example: development of Viagra to treat erectile dysfunction

34. Finding a Lead (cont.) Sildenafil (compound UK-92,480) was synthesized by a group of pharmaceutical chemists working at Pfizer's Sandwich, Kent research facility in England. It was initially studied for use in hypertension (high blood pressure) and angina pectoris (a form of ischaemic cardiovascular disease). Phase I clinical trials under the direction of Ian Osterloh suggested that the drug had little effect on angina, but that it could induce marked penile erections.

35. Pfizer therefore decided to market it for erectile dysfunction, rather than for angina. The drug was patented in 1996, approved for use in erectile dysfunction by the Food and Drug Administration on March 27, 1998, becoming the first pill approved to treat erectile dysfunction in the United States, and offered for sale in the United States later that year. It soon became a great success: annual sales of Viagra in the period 1999–2001 exceeded $1 billion.

36. Finding a Lead (cont.)

38. Structure-Activity-Relationships (SAR’s) • Once a lead has been discovered, it is important to understand precisely which structural features are responsible for its biological activity (i.e. to identify the “pharmacophore”)

40. The pharmacophore is the precise section of the molecule that is responsible for biological activity

41. This may enable one to prepare a more active molecule • This may allow the elimination of “excessive” functionality, thus reducing the toxicity and cost of production of the active material • This can be done through synthetic modifications • Example: R-OH can be converted to R-OCH3 to see if O-H is involved in an important interaction • Example: R-NH2 can be converted to R-NH-COR’ to see if interaction with positive charge on protonated amine is an important interaction

42. Link

43. Next step: Improve Pharmacokinetic Properties • Improve pharmacokinetic properties.pharmacokinetic = The study of absorption, distribution, metabolism and excretion of a drug (ADME). • Video • exercise=MedicationDistribution&title=Medication%20Absorption,%20Distribution,%20Metabolism%20and%20Excretion%20Animation&publication_ID=2450

44. Metabolism of Drugs • The body regards drugs as foreign substances, not produced naturally. • Sometimes such substances are referred to as “xenobiotics” • Body has “goal” of removing such xenobiotics from system by excretion in the urine • The kidney is set up to allow polar substances to escape in the urine, so the body tries to chemically transform the drugs into more polar structures.

45. Metabolism of Drugs (cont.) • Phase 1 Metabolism involves the conversion of nonpolar bonds (eg C-H bonds) to more polar bonds (eg C-OH bonds). • A key enzyme is the cytochrome P450 system, which catalyzes this reaction: RH + O2 + 2H+ + 2e– → ROH + H2O

46. Mechanism of Cytochrome P450

47. Phase I metabolism may either detoxify or toxify. • Phase I reactions produce a more polar molecule that is easier to eliminate. • Phase I reactions can sometimes result in a substance more toxic than the originally ingested substance. • An example is the Phase I metabolism of acetonitrile

50. The Liver • Oral administration frequently brings the drugs (via the portal system) to the liver